Circular RNA-based HPV16 therapeutic vaccine elicits potent and durable antitumor immunity.

ABSTRACT:

Background

Human papillomavirus (HPV) 16 infection is associated with several human malignancies. Developing therapeutic vaccines holds great potential for patients who do not benefit from standard care. Circular RNA (circRNA) is an emerging next-generation platform for cancer vaccine development owing to its superior stability and convenient manufacturing process. Herein, we report development of a synthetic circRNA encoding fused HPV16 E7/E6 antigens encapsulated with lipid nanoparticles (LNP) to treat HPV16-related solid tumors.

Methods

The immunogenicity and anti-tumor immune response of the LNP-circRNA vaccine was determined in naïve C57BL/6 mice and TC-1 tumor-bearing mice, respectively. Changes in immune cells were examined using flow cytometry and immunofluorescence

SUBMITTER: Zhou R 

PROVIDER: S-EPMC12870021 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature